Studies[6–8] have suggested that SGLT-2 inhibitors may reduce oxidative stress, improve endothelial function, and offer protection against HF and chronic kidney disease in diabetic and non-diabetic populations. The gene discussed is SLC5A2; the disease is hydrops fetalis.